Publications by authors named "T M Mark"

Peptide bond formation from the pure protonated glycine dimer, H(Gly), and from the mixed protonated glycine-diglycine dimer, HGly(Gly), was recently found experimentally to occur in gas-phase experiments in the absence of any catalyst and especially under anhydrous conditions [, 2023, , 775]. In this contribution we further examine the conditions of such unimolecular reactions by means of density-functional theory calculations at the DFT/M06 2X/6-311G++(2df,p) level, focusing in particular on the role played by the protonation site. Two pathways, stepwise and concerted, are identified for the pure protonated dimer, and six pathways are examined for the mixed dimer.

View Article and Find Full Text PDF

scRNA-seq was used to study a patient with high-risk multiple myeloma featuring LCE. LCE was rooted in a transcriptomic subpopulation that corresponded to a genetic subclone and established novel links between LCE and LAMP5 overexpression to osteolysis and prognosis, validated in RNA-seq databases.

View Article and Find Full Text PDF
Article Synopsis
  • Medicaid expansion has improved access to substance use disorder treatment, yet tracking overdose deaths among this population remains unreported.
  • A study using data from 2016-2020 revealed that the drug overdose death rate among Medicaid beneficiaries in 2020 was 54.6 per 100,000, significantly higher than the 27.9 per 100,000 rate for the general US population.
  • The findings indicate an urgent need for further research and strategies to address the disproportionately high overdose rates in the Medicaid population, with a notable increase of 54% in overdose deaths from 2016 to 2020.
View Article and Find Full Text PDF
Article Synopsis
  • Epcoritamab, a bispecific antibody targeting CD3 and CD20, showed promising long-term results as a monotherapy for relapsed or refractory large B-cell lymphoma (LBCL) in the EPCORE NHL-1 study, with a 63.1% overall response rate and a 40.1% complete response rate after a median follow-up of 25.1 months.
  • The estimated 24-month progression-free survival (PFS) and overall survival (OS) rates were 27.8% and 44.6%, respectively, with 64.2% of complete responders maintaining their response at that time.
  • Most treatment-emergent adverse events were manageable, with cytokine release syndrome
View Article and Find Full Text PDF